Creo Medical GroupCMEOF 53 Net Debt Paydown Yield % is 7.19% as of Jul. 07, 2026. GuruFocus rates CMEOF with a GF Score™ of 53/100 and a GF Value™ of $0.24. The stock has 6 warning signs investors should review. Among 773 Medical Devices & Instruments companies, Creo Medical Group ranks better than 89.78% on this metric.
Net Debt Paydown Yield % is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. It is a measure of a company's willingness and ability to reduce its debt.
As of today, Creo Medical Group's Net Debt Paydown Yield % was 7.19%.
Creo Medical Group (OTCPK:CMEOF) Net Debt Paydown Yield % Explanation
Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced. In other words, it is a measure of the willingness and ability of a firm's management to pay down debt. Companies that have high debt paydown yields indicate that they are more aggressive with paying down debt.
In the calculation of Net Debt Paydown Yield %, we use the reductions of TTM average total debt one-year-ago and TTM average total debt at present, divided by its Market Cap.
Creo Medical Group Net Debt Paydown Yield % Related Terms
Creo Medical Group Net Debt Paydown Yield % Historical Data
* Premium members only.
The historical data trend for Creo Medical Group's Net Debt Paydown Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CMEOF vs ABT, SYK, MDT: Net Debt Paydown Yield % Comparison
For the Medical Devices subindustry, Creo Medical Group's Net Debt Paydown Yield %, along with its competitors' market caps and Net Debt Paydown Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Creo Medical Group Net Debt Paydown Yield % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Creo Medical Group's Net Debt Paydown Yield % distribution charts can be found below:
* The bar in red indicates where Creo Medical Group's Net Debt Paydown Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Net Debt Paydown Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.
What does a Net Debt Paydown Yield % of 7.19% mean?
Creo Medical Group (CMEOF) has a Net Debt Paydown Yield % of 7.19% as of Jul. 07, 2026. Net Debt Paydown Yield is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. This metric provides insight into a company's willingness and ability to reduce its debt using free cash flow. View historical data on Creo Medical Group and its competitors. According to the industry distribution chart, Creo Medical Group ranks #79 out of 773 companies in the Medical Devices & Instruments industry, placing it in the top 10.2%.
Is Creo Medical Group's Net Debt Paydown Yield % too high?
Creo Medical Group's current Net Debt Paydown Yield % is 7.19%. The Medical Devices & Instruments industry median Net Debt Paydown Yield % is 0.01. Creo Medical Group's value of 7.19% is 71800% above this industry median. Based on the distribution chart, Creo Medical Group ranks #79 out of 773 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Creo Medical Group has a GF Score™ of 53/100, reflecting its overall financial health beyond just this single metric.
How does Creo Medical Group's Net Debt Paydown Yield % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Creo Medical Group ranks #79 out of 773 companies for Net Debt Paydown Yield %. This places Creo Medical Group in the top 10% of its industry — outperforming the majority of peers. The industry median Net Debt Paydown Yield % is 0.01. Creo Medical Group's value of 7.19% is 71800% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Debt Paydown Yield % for a Medical Devices & Instruments company?
The median Net Debt Paydown Yield % among Medical Devices & Instruments companies is 0.01, based on 773 companies in the industry. Companies in the top quartile (top 25%) have a Net Debt Paydown Yield % significantly above this median, while those in the bottom quartile fall well below. However, Net Debt Paydown Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Creo Medical Group's current Net Debt Paydown Yield % of 7.19% is 71800% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Debt Paydown Yield % mean?
A high Net Debt Paydown Yield % can signal that a stock is expensive relative to its fundamentals. Net Debt Paydown Yield is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. This metric provides insight into a company's willingness and ability to reduce its debt using free cash flow. View historical data on Creo Medical Group and its competitors. For the Medical Devices & Instruments industry, the median Net Debt Paydown Yield % is 0.01 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Creo Medical Group's current Net Debt Paydown Yield % is 7.19%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Creo Medical Group stock overvalued right now?
Creo Medical Group (CMEOF) has a current Net Debt Paydown Yield % of 7.19%. The stock's GF Value™ is $0.24, compared to a current price of $0.20 — trading 16.7% below its estimated fair value. The current Net Debt Paydown Yield % is 7.19% and 71800% above the Medical Devices & Instruments industry median of 0.01. Creo Medical Group's overall GF Score™ is 53/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Debt Paydown Yield % calculated?
Net Debt Paydown Yield % is calculated from a company's financial statements. For Creo Medical Group (CMEOF), the current Net Debt Paydown Yield % is 7.19% as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Creo Medical Group (CMEOF) Overvalued in 2026?
Based on GuruFocus' analysis, Creo Medical Group stock appears to be undervalued.
The current stock price of $0.20 is trading 16.7% below its estimated GF Value™ of $0.24.
Key valuation signals for CMEOF:
Net Debt Paydown Yield %: 7.19%
GF Value™: $0.24 vs. price of $0.20 (16.7% below fair value)
Industry Position: 71800% above the Medical Devices & Instruments median (#79 of 773)
No single metric tells the full story. See the CMEOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Creo Medical Group PLC is a medical device company engaged in providing services in the field of surgical endoscopy. The company has developed a platform called Croma which is an electrosurgical platform to deliver microwave and bipolar radiofrequency through a single accessory port. The reportable segment of the company is the research and development of electrosurgical medical devices relating to the field of surgical endoscopy. Geographically, the company generates a majority of its revenue from United Kingdom and the rest from Europe and the rest of the world.
53GF Score
Get the complete analysis for CMEOF
Net Debt Paydown Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CMEOF has been successfully added to your 
